Testing a new therapy to reduce severe lung injury in patients with Acute Respiratory Distress Syndrome.
A Randomized Phase 2A Clinical Trial Pioneering the Utility of an eNAMPT-Reducing Therapy in ARDS/VILI: the PUERTA Trial
This study is testing a new treatment for Acute Respiratory Distress Syndrome (ARDS) using a special antibody called ALT-100 mAb, which aims to help reduce lung inflammation and improve recovery for patients with this condition.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aqualung Therapeutics Corp. NIH-funded |
| Lab location | 1 site (Juno Beach, UNITED STATES) |
| Project ID | NIH-10925146 on NIH RePORTER |
What this research studies
This research investigates a novel treatment for Acute Respiratory Distress Syndrome (ARDS) using a humanized monoclonal antibody called ALT-100 mAb. The therapy targets a specific protein, eNAMPT, which is involved in inflammation and lung injury. By neutralizing eNAMPT, the treatment aims to reduce the severity of ARDS and improve patient outcomes. The research includes a clinical trial where patients will receive this therapy to assess its safety and effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with Acute Respiratory Distress Syndrome, particularly those affected by conditions like COVID-19.
Not a fit: Patients with mild respiratory issues or those not diagnosed with ARDS may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce mortality and improve recovery rates for patients suffering from ARDS.
How similar studies have performed: Previous research has shown promise in targeting eNAMPT for reducing inflammation in ARDS, suggesting a potential for success in this novel approach.
Where this research is happening
Juno Beach, UNITED STATES
- Aqualung Therapeutics Corp. — Juno Beach, United States (Active)
Researchers
- Principal investigator: Garcia, Joe G. N. — Aqualung Therapeutics Corp.
- Study coordinator: Garcia, Joe G. N.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.